Intravenous Immunoglobulin Market Trends

Key Emerging Trends in the Intravenous Immunoglobulin Market

Myasthenia gravis (MG), a rare autoimmune disorder impacting the neuromuscular junction, is characterized by the fatigable weakness of voluntary muscles. While MG can manifest at any age, it predominantly affects adults. In the adult-onset form, females are more commonly affected before the age of 40, while males are more susceptible after the age of 50.
The increasing prevalence of MG has prompted various governments and private associations to embark on awareness campaigns to educate the public about the disease and its associated complications. In 2017, the Myasthenia Gravis Foundation of America (MGFA) took a significant step by organizing the 7th MG Walk Campaign. This national awareness and fundraising initiative played a crucial role in spreading awareness about MG. The MG Walk Campaign, a collective effort involving thousands of participants and over 530 teams in 2016, successfully raised more than USD 800,000. This not only demonstrates the commitment of the MGFA but also highlights the engagement of the community in supporting MG awareness and research.
Furthermore, MGFA has established a patient registry designed to foster research and development, enhance treatment options, advocate for patients, and promote public awareness of MG. This registry serves as a valuable repository of essential information for clinicians and researchers, contributing to the overall understanding of MG and its management.
Beyond the borders of the United States, organizations such as the European Myasthenia Gravis Association (EuMGA) are actively involved in promoting the health and welfare of individuals affected by myasthenia gravis. EuMGA collaborates with patient groups in various European countries, working towards creating awareness about the best medical practices in the diagnosis and treatment of MG and related disorders. The collective efforts of these associations aim not only to support individuals with myasthenia gravis and their families but also to increase public awareness and raise funds for vital research initiatives.
In the current landscape, it is evident that multiple associations are taking proactive measures to support those affected by myasthenia gravis. These actions go beyond mere awareness campaigns and extend to the establishment of crucial resources like patient registries, emphasizing the multifaceted approach required to address the complex challenges posed by MG. As these organizations continue their dedicated efforts, there is a collective hope that increased awareness, advocacy, and research funding will contribute significantly to improving the lives of individuals living with myasthenia gravis.